Arcus Biosciences stock fell 3.13 percent on October 2
Arcus Biosciences (RCUS) stock dropped 3.13% on October 2, 2026, closing at USD 24.44, ahead of a significant investor event on October 20 presenting new casdatifan data for kidney cancer treatment. Despite beating Q2 revenue expectations with USD 41 million, the company reported a GAAP net loss of USD 91 million, though its cash runway extends into late 2028. Analysts maintain a "Moderate Buy" consensus with an average price target of USD 38.30.
Arcus Biosciences, Inc. (RCUS) Stock Price, News, Quote & History
This article provides a detailed financial overview of Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company. It includes current stock price, historical performance data, key financial metrics, earnings trends, analyst ratings, and a company overview detailing its pipeline of cancer therapies.
Arcus Biosciences (RCUS) Sets Casdatifan Data Event As Undervalued Narrative Faces A Test
Arcus Biosciences (RCUS) has scheduled an event for October 20th to release new data on its kidney cancer drug, casdatifan, which could act as a significant catalyst. Despite recent short-term stock declines, long-term shareholders have seen substantial returns. The company is currently considered undervalued by many, with a fair value estimate significantly higher than its current trading price, though some metrics suggest the stock is already priced steeply for unproven programs.
Arcus Biosciences, Inc. (RCUS) Stock forecasts
Argus has raised its target price for Arcus Biosciences, Inc. (RCUS) to $28.00. The company is a clinical-stage biopharmaceutical firm focused on developing immunotherapies for cancer. The report was published on September 23, 2026.
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences announced that its Compensation Committee granted inducement equity awards to four new employees. These awards include options to purchase 21,200 shares of common stock at $26.39 per share and restricted stock units for 10,650 shares. The grants were made under the company's 2020 Inducement Plan, in compliance with NYSE rules.
Arcus Biosciences stock trades 16.8 percent below yearly high
Arcus Biosciences stock is trading 16.8 percent below its 52-week high after reporting Q2 2026 revenue of USD 41 million, significantly beating consensus estimates. The company is focusing its resources on casdatifan, an investigational kidney cancer treatment, and has an investor event scheduled for October 20, 2026, to present new data. Despite strong revenue, Arcus Biosciences remains loss-making due to late-stage clinical development, with its USD 775 million liquidity expected to fund operations into at least the second half of 2028.
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
Arcus Biosciences will host an investor event on October 20, 2026, to present new data for casdatifan, a next-generation HIF-2α inhibitor, in treating clear cell renal cell carcinoma (ccRCC). The event will cover data from the ARC-20 platform study, evaluating casdatifan alone or in combination across various treatment lines, and will feature insights from Arcus management and a leading academic expert in kidney cancer. Key data points will include efficacy and safety results for casdatifan in first-line, second-line, and late-line settings, including combinations with other therapies and subgroup analyses.
New kidney cancer data from 121 patients will be shared Oct. 20
Arcus Biosciences will host an investor event on October 20, 2026, to present new data from its ARC-20 platform study on casdatifan, a HIF-2α inhibitor for kidney cancer treatment. The presentation will include safety and efficacy data for casdatifan in various combinations and as monotherapy, supporting ongoing and planned registrational trials. Key data points will cover first-line TKI-free combinations, second-line TKI-containing combinations, and late-line monotherapy, with detailed results for up to 121 patients.
TD Cowen Initiates Arcus Biosciences at Buy
TD Cowen has initiated coverage on Arcus Biosciences (RCUS) with a "Buy" rating. This decision follows recent presentations by Arcus Biosciences at several healthcare conferences and updates on its clinical programs and financial outlook. The company is a clinical-stage biopharmaceutical firm focused on developing differentiated molecules and combination therapies for cancer, with several investigational products in clinical development.
Arcus Biosciences stock initiated at Buy by TD Cowen on RCC drug
TD Cowen initiated coverage on Arcus Biosciences (NYSE:RCUS) with a Buy rating, citing the potential of its RCC drug, casdatifan, to outperform competitors. The firm believes casdatifan could become the preferred HIF-2α inhibitor in renal cell carcinoma due to superior target engagement and progression-free survival rates compared to Welireg. Positive upcoming data in October is expected to de-risk Phase III trials and position casdatifan to dominate the over $10 billion renal cell carcinoma market.
Arcus Biosciences (RCUS) Looks Undervalued On Paper, Is The Market Pricing In Too Much Risk?
Arcus Biosciences (RCUS) shares closed at US$24.59, significantly below the average analyst and intrinsic value estimates of $38, suggesting it is undervalued by 35%. This valuation is largely driven by expectations for its kidney cancer pipeline, specifically the HIF-2 alpha inhibitor casdatifan. However, the market assigns a high P/S ratio of 26.8x, indicating substantial expectations for future performance despite the company currently being loss-making.
Arcus Biosciences at cantor global healthcare conference: casdatifan in focus By Investing.com
Arcus Biosciences outlined its strategy for its lead cancer drug, casdatifan, at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, emphasizing that the upcoming October 20 data readout will be crucial. The company is focusing 80% of its portfolio spending on casdatifan, which it believes has significant potential across multiple lines of treatment for kidney cancer, with estimated commercial opportunities of $1.5 billion to $2 billion in second-line and over $4 billion in frontline disease. Management highlighted casdatifan's stronger pharmacology profile compared to Merck's belzutifan and its inclusion of a broader, more real-world patient population in its studies.
One new employee can buy 26,350 Arcus shares. Arcus also awarded rights to 13,200 shares.
Arcus Biosciences (NYSE: RCUS) announced an inducement grant to a new employee, including options to purchase 26,350 shares of common stock at an exercise price of $29.06 and restricted stock units for 13,200 shares. These equity awards were issued under the company's 2020 Inducement Plan, leveraging the "inducement exception" of NYSE Listed Company Manual Rule 303A.08. Arcus Biosciences is a clinical-stage biopharmaceutical company focusing on cancer and inflammatory diseases.
Following VIRO 2025 Success, Arcus Biosciences Continues Partnership in 2026
Arcus Biosciences will continue its partnership with VIRO – Global Voices in Renal Oncology as an Innovation Supporter for the 2026 edition, following a successful collaboration in 2025. VIRO 2026, a global virtual congress organized by OncoDaily, will take place on September 10–11, 2026, bringing together international specialists to discuss advances and challenges in kidney cancer care. Arcus Biosciences, a clinical-stage biopharmaceutical company focused on oncology, develops therapies for cancer, with kidney cancer being a key area of its current development strategy.
Truist raises Arcus Biosciences stock price target on trial data By Investing.com
Truist Securities has increased its price target for Arcus Biosciences (NYSE:RCUS) from $35 to $40, maintaining a Buy rating, ahead of the company's ARC-20 trial data presentation in October. The firm anticipates a positive outcome from the casdatifan plus cabozantinib combination, expecting that a pooled median progression-free survival of around 15.5 months would be sufficient for a competitive profile. This comes after Arcus Biosciences reported a narrower-than-expected loss and higher revenues for Q2 2026, with strong cash reserves.
Truist raises Arcus Biosciences stock price target on trial data By Investing.com
Truist Securities has increased its price target for Arcus Biosciences (RCUS) stock from $35 to $40, maintaining a Buy rating, ahead of the company's ARC-20 trial data presentation in October. The firm anticipates the casdatifan plus cabozantinib combination data, especially for clear cell renal cell carcinoma, to be a key indicator for the pivotal PEAK-1 trial. Truist believes a pooled median progression-free survival of approximately 15.5 months would be sufficient for a competitive profile, with 16 months or more providing clear differentiation, and sees potential stock movements of around 30% based on trial success probabilities.
Truist raises Arcus Biosciences stock price target on trial data
Truist Securities has increased its price target for Arcus Biosciences (NYSE:RCUS) from $35 to $40, maintaining a Buy rating, ahead of the company's October presentation of ARC-20 trial data for renal cell carcinoma. The firm highlighted the casdatifan plus cabozantinib combination as a key indicator for the PEAK-1 trial and expects approximately 15.5-month pooled median progression-free survival to be a competitive outcome. This decision follows Arcus Biosciences' strong second-quarter performance, which saw a narrower-than-expected loss and significant revenue beat, alongside a robust cash position sustaining operations until at least H2 2028.
Why Arcus Biosciences (RCUS) Is Getting Attention Today
Arcus Biosciences (RCUS) stock is gaining attention after recent share price movements, closing at US$30.12. Investors are focused on its clinical-stage cancer pipeline, particularly the HIF-2 alpha inhibitor casdatifan, which analysts believe could significantly undervalue the stock at $38. However, despite a positive long-term outlook, its high Price-to-Sales ratio of 32.8x compared to industry averages and potential regulatory risks for its drug pipeline warrant caution.
Arcus Biosciences will take part in 3 New York conferences in September
Arcus Biosciences (NYSE: RCUS) announced its management team will participate in three investor conferences in New York during September 2026. These include Citi’s 2026 Biotech Back to School Conference, Cantor Fitzgerald Global Healthcare Conference 2026, and Morgan Stanley's 24th Annual Global Healthcare Conference. The company will engage in fireside chats and one-on-one meetings at each event.
Arcus Biosciences CAO Azoy sells $84,810 in stock
Alexander Azoy, Chief Accounting Officer at Arcus Biosciences (NASDAQ:RCUS), sold 2,827 shares of common stock for $84,810 on August 21, 2026, under a Rule 10b5-1 trading plan. This sale followed the exercise of options for an equal number of shares at a lower price. The company's stock is trading near its 52-week high, with recent positive financial results for Q2 2026 surpassing analysts' expectations for both earnings and revenue.
Arcus Biosciences (NASDAQ: RCUS) CAO sells shares from option plan
Arcus Biosciences Chief Accounting Officer, Alexander Azoy, exercised stock options for 2,827 shares at $15.44 per share and simultaneously sold these shares at $30.00 per share. This transaction, executed under a Rule 10b5-1 trading plan on August 21, 2026, resulted in approximately $41,000 in pre-tax spread. Following the sale, Azoy retains 3,073 stock options expiring in 2034.
Arcus Biosciences (RCUS) officer eyes sale after June plan trades
Arcus Biosciences officer Alexander Azoy has filed a Rule 144 notice for a planned sale of 2,827 shares of common stock, valued at $83,453.04, following the exercise of stock options. This follows previous 10b5-1 plan sales of 2,562 shares for $66,023.76 on June 1, 2026. The sale is scheduled for August 21, 2026, through Morgan Stanley Smith Barney LLC.
Arcus Biosciences (RCUS) Stock Looks Strong On Returns But Stretched On Sales
Arcus Biosciences (RCUS) has seen a strong 200.8% return over the past year, driven by a partnership with Summit Therapeutics, but its valuation appears stretched with a P/S ratio of 33.0x against an industry average of 11.6x. The company's current valuation implies high investor optimism, which needs to be supported by significant progress in its pipeline, particularly the kidney cancer program, to justify its rich pricing.
Arcus Biosciences (RCUS) Stock Looks Strong On Returns But Stretched On Sales
Arcus Biosciences (RCUS) has seen a strong 200.8% return over the past year, indicating significant investor optimism, partly due to a recent partnership with Summit Therapeutics. However, the stock appears richly valued with a P/S ratio of 33.0x, significantly higher than the biotech industry average, suggesting that much of the optimism is already priced in. The company's valuation framework highlights a wide gap between its current P/S and what its risk profile would typically justify, raising questions about whether future clinical progress can support the current revenue multiple.
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
Kuehn Law, PLLC, a shareholder litigation law firm, has initiated an investigation into whether certain officers and directors of Arcus Biosciences, Inc. (NYSE: RCUS) breached their fiduciary duties to shareholders, specifically concerning potential self-dealing. The firm encourages long-term RCUS stockholders to contact them for a free consultation regarding potential damages and corporate governance reforms. Investors are urged to act promptly as there may be limited time to enforce their rights.
Investigation launched into Arcus Biosciences officers for possible self-dealing breaches
Kuehn Law, PLLC has initiated an investigation into officers and directors of Arcus Biosciences, Inc. for potential breaches of fiduciary duties through self-dealing. This investigation could result in shareholder damages and require corporate governance reforms. Long-term shareholders are advised to contact the law firm to understand their rights and potential actions.
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating whether officers and directors of Arcus Biosciences, Inc. (NYSE: RCUS) breached their fiduciary duties due to potential self-dealing. The firm is encouraging long-term RCUS stockholders to contact them to discuss potential damages and corporate governance reforms, emphasizing that consultation and case costs are free for investors.
Handelsbanken Fonder AB Takes $1.20 Million Position in Arcus Biosciences, Inc. $RCUS
Handelsbanken Fonder AB has acquired a new stake worth approximately $1.20 million in Arcus Biosciences, Inc. (NYSE:RCUS) during the second quarter. Institutional investors collectively own 92.89% of the company, and analysts maintain a "Moderate Buy" consensus rating with a $37.80 average price target. The company reported a quarterly loss of $0.72 per share, beating estimates, and revenues of $41 million, which exceeded expectations despite a year-over-year decrease.
What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders
Arcus Biosciences reported a significant revenue drop in Q2 2026, falling to US$41 million from US$160 million a year earlier, and widened net losses. The company also cut its full-year 2026 GAAP revenue guidance to US$65 million to US$75 million. This steep decline and reduced forecast emphasize the company's reliance on its oncology pipeline, particularly casdatifan, and highlights the funding and execution risks shareholders face.
What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders
Arcus Biosciences reported a significant revenue drop in Q2 2026 to US$41 million from US$160 million a year earlier, alongside a net loss of US$91 million. The company has also cut its full-year 2026 revenue guidance to US$65 million to US$75 million, which analysts believe will require a reconsideration of previous optimistic forecasts. Despite these setbacks, the company's oncology pipeline, particularly casdatifan, and a recent collaboration with Summit Therapeutics remain central to its investment narrative and future revenue potential.
What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders
Arcus Biosciences reported a significant drop in Q2 2026 revenue and widened net losses, leading to a lowered full-year 2026 revenue forecast of US$65 million to US$75 million. This financial update underscores the company's reliance on its oncology pipeline, particularly casdatifan, and its recent collaboration with Summit Therapeutics, which is crucial for future revenue despite ongoing execution and funding risks. Investors are advised to consider the company's ambitious revenue projections against its high cash burn and dependence on external funding, with analysts reassessing their previous optimistic forecasts.
Arcus Biosciences (RCUS) Reported Q2 2026 Results, Is The Stock A Bargain?
Arcus Biosciences (RCUS) recently reported Q2 2026 results, with revenue of US$41 million and a net loss of US$91 million. Despite these figures, the stock has shown significant momentum, with a 16.07% 90-day return and a 24.35% year-to-date return. The company is considered 24% undervalued by many, with a fair value of $38, largely due to its promising kidney cancer pipeline, though regulatory risks and competition remain watchpoints.
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.82, Implies 35% Upside
Arcus Biosciences, Inc. (RCUS) has seen its average 12-month price target raised from $38.33 to $38.82 by 11 analysts, with forecasts ranging from $23 to $47 per share. This new target implies a potential upside of approximately 35% from its August 13 closing price. The consensus rating for RCUS remains a "Buy" from 12 covering analysts, with 9 recommending Buy and 3 recommending Hold.
Arcus Biosciences (RCUS) Reported Q2 2026 Results, Is The Stock A Bargain?
Arcus Biosciences reported Q2 2026 results with $41 million in revenue and a $91 million net loss, along with new full-year revenue guidance. The stock has seen significant price returns (16.07% in 90 days, 24.35% YTD), and a current valuation suggests it is 24% undervalued at $38, compared to its last close of $28.96. This valuation is largely based on the potential of its kidney cancer pipeline, especially the HIF-2 alpha inhibitor, casdatifan, but faces risks from regulatory setbacks and competition.
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?
Arcus Biosciences and Summit Therapeutics have partnered to evaluate a combination of their investigational cancer drugs, casdatifan and ivonescimab, for clear cell renal cell carcinoma. The collaboration aims to establish a new first-line treatment and initial data is anticipated by mid-2027. Financially, Arcus appears stronger with established revenue and a longer cash runway, though both companies are pursuing significant clinical advancements.
A New Arcus Employee Receives Options With a $28.72 Exercise Price
Arcus Biosciences (NYSE: RCUS) announced that its Compensation Committee granted a new employee options to purchase 2,850 shares of common stock at an exercise price of $28.72 per share, which was the closing price on August 10, 2026. The employee also received restricted stock units for 1,450 shares. These grants were made under the Company’s 2020 Inducement Plan, consistent with the "inducement exception" under NYSE rules.
Morgan Stanley Adjusts Price Target on Arcus Biosciences to $23 From $22, Maintains Equalweight Rating
Morgan Stanley has increased its price target for Arcus Biosciences (RCUS) from $22 to $23, while maintaining an Equalweight rating on the stock. Despite this adjustment, the average analyst rating for Arcus Biosciences remains a "buy" with a mean price target of $38.33. The full details of this report are available to premium subscribers.
Goldman Sachs Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Raises Target Price to $42
Goldman Sachs has reiterated its Buy rating on Arcus Biosciences (RCUS.US) and increased its price target to $42. This update reflects the firm's continued confidence in the company's prospects.
Arcus Biosciences (NYSE: RCUS) gets 24.7% ownership from Gilead
Gilead Sciences, Inc. has reported a beneficial ownership of 24.7% in Arcus Biosciences, Inc. (NYSE: RCUS), holding 31,424,760 shares out of 127,333,376 outstanding. This stake was built through multiple equity purchases dating back to 2020 and is linked to an Option, License and Collaboration Agreement providing Gilead with exclusive licensing options on Arcus programs. While a prior option allowing Gilead to increase its stake to 35% expired in July 2025, Gilead states it currently has no specific plans for major corporate actions, but may review its investment over time.
Arcus Biosciences (RCUS) Stock Can Casdatifan Carry Mounting Losses
Arcus Biosciences (RCUS) reported Q2 2026 revenue of US$41m against a net loss of US$91m, indicating a substantial decline from the previous year. While the stock initially saw a pop, concerns persist regarding the company's high burn rate, reliance on partners, and concentrated pipeline focused on the casdatifan asset. The article highlights the contrasting bull and bear cases, emphasizing the potential for dilution risk despite the company's cash reserves.
Arcus Biosciences Inc (RCUS) News, Articles, Events & Latest Updates
Arcus Biosciences (RCUS) recently reported its Q2 2026 financial results, exceeding revenue estimates despite a reported loss. The company is actively advancing its pipeline, including new clinical collaborations for casdatifan and ivonescimab in cancer treatments. An analyst from HC Wainwright also increased Arcus Biosciences' price target, while an insider sold a significant number of shares.
Arcus Biosciences, Inc. Stock 12‑Month Price Target Cut to $37.17, Implies 32% Upside
Analysts have adjusted their 12-month average price target for Arcus Biosciences, Inc. (RCUS) stock down slightly from $37.91 to $37.17, based on estimates from 12 analysts. This new target suggests a potential upside of approximately 32% from the July 31st closing price. The consensus rating from 13 covering analysts remains a "Buy," with 10 Buys and 3 Holds.
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $26.00
Wells Fargo & Company has raised its price target for Arcus Biosciences (NYSE:RCUS) from $23.00 to $26.00, while maintaining an "equal weight" rating. This new target implies a potential downside of 5.75% from the stock's previous close. Despite this, the company has a "Moderate Buy" consensus rating from analysts with an average price target of $36.90. Arcus Biosciences recently reported better-than-expected quarterly earnings and revenue, though revenue was down year-over-year.
Earnings Flash (RCUS) Arcus Biosciences, Inc. Reports Q2 Revenue $41.0M
Arcus Biosciences, Inc. (RCUS) reported Q2 revenue of $41.0 million. Wedbush adjusted its price target on Arcus Biosciences to $43 from $41, maintaining an Outperform rating. The company is a clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for cancer, with several investigational products in clinical development.
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.25, Implies 38% Upside
The average 12-month price target for Arcus Biosciences, Inc. stock has increased from $37.17 to $38.25, based on estimates from 12 analysts. This new target suggests a potential upside of approximately 38% from the August 5 closing price. The consensus rating among 13 analysts remains a "Buy," with 10 Buy recommendations and 3 Holds.
Arcus Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:RCUS) 2026-08-05
Arcus Biosciences, Inc. (NYSE:RCUS) published its Q2 2026 earnings call presentation, reporting an EPS of -$0.72, which beat estimates by $0.09. The company's revenue for the quarter was $41.00M, exceeding expectations by $19.02M, despite a 74.38% year-over-year decrease. This presentation was released in conjunction with their earnings call on August 5, 2026.
Arcus Adds Three Kidney Cancer Trials as 2026 Data Near
Arcus Biosciences reported its second-quarter 2026 financial results, with revenues of $41 million and a net loss of $91 million. The company is strategically advancing its HIF-2α inhibitor, casdatifan, for clear cell renal cell carcinoma (ccRCC) through three new clinical trial collaborations and anticipates multiple data readouts in the second half of 2026. Arcus expects its cash reserves of $775 million to fund operations until at least the second half of 2028.
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
Arcus Biosciences, Inc. (RCUS) reported a Q2 loss of $0.72 per share, outperforming the Zacks Consensus Estimate of a $0.98 loss. The company also exceeded revenue expectations, posting $41 million against a consensus estimate. Despite a mixed outlook for estimate revisions, RCUS shares have increased by 20.9% year-to-date.
Arcus Biosciences (NYSE: RCUS) posts Q2 loss, ends Gilead options
Arcus Biosciences reported a Q2 2026 net loss of $91 million, or $0.72 per share, with total revenues of $41 million, a significant decrease from $160 million in Q2 2025 due to the absence of a large one-time payment from Gilead. Broad Gilead option rights over Arcus's early-stage pipeline have ended, although Gilead retains time-limited options on specific programs and a substantial equity stake. Arcus is advancing its HIF-2α inhibitor casdatifan through new collaborations while discontinuing two Phase 3 TIGIT trials, managing expenses, and expects its $775 million in cash and investments to fund operations until at least the second half of 2028.
Arcus Biosciences earnings in focus as kidney cancer drug advances
Arcus Biosciences is reporting second-quarter earnings, with analysts expecting a narrower loss and increased revenue sequentially, though down year-over-year due to collaboration income. Investors are keen on updates regarding the company's lead kidney cancer candidate, casdatifan, and its clinical trials, as well as the company's cash burn. Despite past misses, Wall Street remains bullish, anticipating significant upside for the stock given the potential of its pipeline.
